Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $55.00.

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, June 17th.

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $11.24 on Thursday. The company has a market cap of $530.98 million, a price-to-earnings ratio of -7.07 and a beta of 1.39. Silence Therapeutics has a 12 month low of $4.19 and a 12 month high of $12.19. The stock’s 50-day moving average is $9.11 and its 200-day moving average is $7.08.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The firm had revenue of $0.42 million for the quarter, compared to analysts’ expectations of $1.25 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. Research analysts anticipate that Silence Therapeutics will post -1.08 EPS for the current year.

Institutional Trading of Silence Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after purchasing an additional 1,698 shares during the period. Seven Fleet Capital Management LP grew its stake in shares of Silence Therapeutics by 6.2% in the first quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after buying an additional 9,159 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Silence Therapeutics by 903.8% in the first quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after buying an additional 26,807 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Silence Therapeutics by 628.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after buying an additional 148,514 shares during the period. Finally, SG Americas Securities LLC raised its holdings in shares of Silence Therapeutics by 11.8% during the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after buying an additional 30,358 shares during the period. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.